Similar articles for PMID: 22698575

Year	Number of Results
1978	1
1994	2
1999	1
2001	2
2002	2
2003	2
2004	2
2005	3
2006	6
2007	4
2008	13
2009	9
2010	7
2011	7
2012	11
2014	2
2015	2
2016	1
2019	1
2021	1
2024	0

1

The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading.

Liedberg F, Lauss M, Patschan O, Aine M, Chebil G, Cwikiel M, Engilbertsson H, Gudjonsson S, Kollberg P, Sjödahl G, Månsson W, Lindgren D, Höglund M; Lund Bladder Cancer Group. Liedberg F, et al. Eur Urol. 2012 Oct;62(4):620-3. doi: 10.1016/j.eururo.2012.05.063. Epub 2012 Jun 5. Eur Urol. 2012. PMID: 22698575 No abstract available.

2

Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Montironi R, Lopez-Beltran A, Cheng L. Montironi R, et al. Eur Urol. 2008 Oct;54(4):843-4. doi: 10.1016/j.eururo.2007.12.027. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18166261 No abstract available.

3

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Burger M, et al. Eur Urol. 2008 Oct;54(4):835-43. doi: 10.1016/j.eururo.2007.12.026. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18166262

4

Prognostic markers for urothelial cancer: obstacles and opportunities.

Malmström PU. Malmström PU. Urol Oncol. 2012 Jul-Aug;30(4):516-7. doi: 10.1016/j.urolonc.2011.04.007. Urol Oncol. 2012. PMID: 22742563 No abstract available.

5

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. van Rhijn BW, et al. J Clin Oncol. 2003 May 15;21(10):1912-21. doi: 10.1200/JCO.2003.05.073. J Clin Oncol. 2003. PMID: 12743143

6

Editorial comment on: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

Montironi R. Montironi R. Eur Urol. 2007 Sep;52(3):768. doi: 10.1016/j.eururo.2007.01.010. Eur Urol. 2007. PMID: 17240042 No abstract available.

7

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.

Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, Matalka I, Musleh H, Haddad Y. Bodoor K, et al. Cancer Epidemiol. 2010 Dec;34(6):724-32. doi: 10.1016/j.canep.2010.05.003. Epub 2010 Jun 9. Cancer Epidemiol. 2010. PMID: 20542753

8

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF. Zieger K, et al. Clin Cancer Res. 2005 Nov 1;11(21):7709-19. doi: 10.1158/1078-0432.CCR-05-1130. Clin Cancer Res. 2005. PMID: 16278391

9

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F. Rebouissou S, et al. J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8. J Pathol. 2012. PMID: 22422578

10

Are there molecular signatures for predicting bladder cancer prognosis?

Lokeshwar VB. Lokeshwar VB. J Urol. 2006 Dec;176(6 Pt 1):2347-8. doi: 10.1016/j.juro.2006.08.142. J Urol. 2006. PMID: 17085098 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

65 results

Results by year